Anzeige
Mehr »
Dienstag, 02.09.2025 - Börsentäglich über 12.000 News
Milliardenmarkt Multiple Sklerose: Neue Therapieform könnte alles verändern!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
109 Leser
Artikel bewerten:
(0)

Thorn Medical PLC Appoints Lord Beaverbrook to Re-join the Board

LONDON, February 10, 2016 /PRNewswire/ --

Thorn Medical PLC ("Thorn" or the "Company"), the international healthcare group, today announces the appointment of Lord Beaverbrook to the Board, with immediate effect.

From 2000 to 2007 he was Chairman of Net Integration Technologies Inc. of Toronto, now part of IBM. He is currently Chairman of Cherif Investment Properties Limited and a Director of Ansgate Barnes Holdco Limited, a property development company.

Prior to that, Lord Beaverbrook was a Lord in Waiting and Government Whip (1986-1988) and the Treasurer of the Conservative Party and the European Democrat Union (1990-1992).

In 1983 he founded and served as Chairman of VenTech Healthcare Corporation, which acquired Abbey Medical Inc., the then largest supplier of home healthcare equipment in the USA. In 1995, Lord Beaverbrook founded MARK Telecom, one of the first of the new 'switchless re-sellers' in the UK. This interest in the Telecom industry led to the formation of Highway One AG, a broadband, multimedia and data transport company of which he was Chairman until 1999 prior to it being sold to Telefonica in 2001.

From 1972 to 1978 Lord Beaverbrook worked for Beaverbrook Newspapers, starting as a management trainee and ultimately rising to General Manager of the Sunday Express. Since 1978 he has served as a director of the Aitken/Beaverbrook Family Office, overseeing a diversified investment fund, specialising in real estate for many years, and, more recently, in oil and gas, and insurance.

He became Honorary Air Commodore of 4624 (County of Oxford) Movements Squadron Royal Auxiliary Air Force in July 2004, and in October 2009 was appointed Honorary Inspector General, Royal Auxiliary Air Force in the rank of Air Vice-Marshal.

Jack Kaye, Thorn Medical's Chairman and Chief Executive, said: "We're delighted to welcome Lord Beaverbrook back to the Board as non-executive director. His international operations experience in the medical and technology fields will be a great help to achieving our challenging global expansion plans now that he has more time to devote to assisting us again."

Lord Beaverbrook added, "I regretted having to leave Thorn Medical to devote my time to other matters, but am glad to be re-joining the Board now in the run-up to our imminent stock market listing which will be the springboard for significant growth in the year ahead."

THE DIRECTORS OF THE ISSUER ACCEPT RESPONSIBILITY FOR THE CONTENTS OF THIS ANNOUNCEMENT

Note to Editors

Thorn Medical PLC

Thorn Medical is a trusted expert investor and acceleration partner dedicated to breaking down the barriers to providing more efficient and effective healthcare worldwide.

With a clear focus on improving human wellbeing, it acts as an aggregator of innovative, scientifically-validated medical technology, pharmaceutical products and healthcare services businesses.

It aims to transform organisational performance through delivering best practice flexible management services that streamline operations, reduce costs, encourage cross-fertilisation, expand market reach and enhance return on capital.

Thorn Medical is dedicated to this market, with a global perspective and an understanding at first hand of the evolving challenges that healthcare businesses face in growing successfully.

Thorn Medical understands how to create value for investors, service providers and patients through building a balanced portfolio of pre-and post-revenue companies that specialise in commercialising innovative and medical technologies and services.

Thorn Medical will continue to grow both organically and through acquisitions, continually developing the enterprise and fully addressing the human health cycle and its genetic, environmental, physical and nutritional influencing factors.

Thorn Medical focuses on four areas

  • Disease prevention
  • Immunity optimisation
  • Disease treatment
  • Research & development

For further information, please visit Thorn Medical's website http://www.thornmedical.com

Contact: Henry Gewanter,Thorn Medical PLC Tel: +44-(0)7774-228845

© 2016 PR Newswire
Solarbranche vor dem Mega-Comeback?
Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:
  • Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
  • Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
  • hina bremst Preisdumping & pusht massiv den Ausbau
Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.